A carregar...
The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
Vedolizumab, an α4β7-integrin antagonist, is the first gut-selective monoclonal antibody that has been approved for the treatment of moderate-to-severe ulcerative colitis and Crohn’s disease in many countries in the world. However, questions still remain regarding its appropriate use and placement i...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4830105/ https://ncbi.nlm.nih.gov/pubmed/27134663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16635081 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|